Press Releases

PTC is committed to serving the interests of all our stakeholders.
Danya
Living with DMD, Ukraine
danya

The press releases contained in this archive section are provided for historical purposes only. The information contained in each press release is accurate only as of the date each press release was originally issued. PTC Therapeutics disavows any obligation to update the information contained in such press releases after the date of their issuance.

Feb 12, 2014
PTC THERAPEUTICS ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK
PTC THERAPEUTICS ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK SOUTH PLAINFIELD, NJ - February 12, 2014 - PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the pricing of an underwritten public offering of 4,489,796 million shares of common stock at a public offering price of $24.50 per
Read More
Jan 24, 2014
PTC THERAPEUTICS EXPANDS MANAGEMENT TEAM
SOUTH PLAINFIELD, NJ – January 24, 2013 – PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced an expansion of its senior management team with the appointment of Robert J. Spiegel M.D., FACP to Chief Medical Officer and Murad Husain to Vice President, Global Regulatory Affairs.
Read More
Dec 23, 2013
PTC THERAPEUTICS ADDED TO NASDAQ BIOTECHNOLOGY INDEX
  SOUTH PLAINFIELD, NJ – December 23, 2013 – PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that it has been selected for addition to the NASDAQ Biotechnology Index® (Nasdaq: NBI), effective prior to the market open today. The NASDAQ Biotechnology Index is designed to track the performance
Read More